Bendamustine and pneumocystis pneumonia: A systematic review

Area of Science:

• Oncology
• Infectious Diseases
• Pharmacology

Background:

• Bendamustine is an alkylating agent used for hematologic malignancies.
• Bendamustine treatment is associated with myelosuppression and increased risk of opportunistic infections like Pneumocystis pneumonia (PCP).
• Current guidelines lack recommendations for PCP chemoprophylaxis in patients undergoing bendamustine therapy.

Purpose of the Study:

• To systematically review existing literature on the incidence and outcomes of PCP in patients treated with bendamustine.
• To evaluate the association between bendamustine therapy and the development of PCP.
• To identify the need for prophylactic strategies against PCP in this patient population.

Main Methods:

• A systematic literature search was conducted across major databases including PubMed, Web of Science, Embase, Google Scholar, and Cochrane Library.
• Keywords used were "Pneumocystis Pneumonia" and "Bendamustine".
• Inclusion criteria led to the selection of 10 relevant studies from an initial pool of 113 papers.

Main Results:

• Ten studies, including case reports, clinical trials, and retrospective analyses, were included.
• PCP was diagnosed in patients post-bendamustine administration, with a mean age of 66.8 years.
• The most common malignancies were non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and breast cancer. The reported mortality rate for PCP in patients treated with bendamustine was 44.44%.

Conclusions:

• Pneumocystis pneumonia is a significant risk for patients with malignancies undergoing bendamustine treatment.
• Bendamustine's lymphopenic effects may contribute to increased susceptibility to PCP.
• Further research is essential to establish definitive PCP risk stratification and guide prophylactic interventions for patients receiving bendamustine.